NEW YORK, Nov. 21, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that its Japanese patent for the technology "Protease Inhibitor – Containing Compositions, Compositions Comprising Same, and [...]
ORMD-0801 dosed once daily reduced A1C by 0.60% compared to only a 0.06% reduction by placebo ORMD-0801 improves metabolic control as evidenced by significant reduction in A1C levels in patients with type 2 diabetes inadequately controlled on multiple other standard of care drugs NEW YORK, [...]
NEW YORK, Nov. 14, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, will hold an investor event and conference call to review the positive results from the initial cohort of the Phase [...]
Achieves primary endpoint with statistically significant reduction in A1C versus placebo Excellent safety profile Conference call today at 8:30 a.m. ET to review Phase IIb data; Extended review event and conference call scheduled for November 18th NEW YORK, November 12, 2019 /PRNewswire/ -- Oramed Pharmaceuticals [...]
NEW YORK, Sept. 18, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that the company's Chief Executive Officer, Nadav Kidron, will present and participate in one-on-one meetings [...]
Topline data readout expected Q4 2019 NEW YORK, Sept. 17, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced the treatment of the last patient in the primary cohort of [...]
NEW YORK, Sept. 3, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that the company will present at three conferences in New York in the first half of September [...]
NEW YORK, July 10, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that Dr. Miriam Kidron, Chief Scientific Officer of Oramed, will deliver two presentations at the World Diabetes [...]
Chairman of HTIT has decades of experience in the diabetes sector in China NEW YORK, July 2, 2019 /PRNewswire/ --Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced that Mr. Xiaoming Gao is joining [...]
Completed recruitment and randomization of all patients in the primary cohort of Phase IIb HbA1c trial for oral insulin capsule ORMD-0801, potentially the first commercial oral insulin capsule for the treatment of Type 2 diabetes; results expected in 4Q 2019; following results Oramed plans to [...]